Partnership Underway to Develop Extensive Protocols and Submissions for US Food & Drug Administration to Uncover Safety and Efficacy for Targeted Medical Cannabis Treatments in the US CB2 chosen to advance application with the US FDA for study on safety and efficacy of cannabis-based topical treatments by leading multistate operator, Vireo. Project marks the start of the clinical trial process for Vireo’s topical creams, lotions and gels to be used by patients for pain management. Company will develop full...
Read more
CB2 Insights Selected by Vireo Health to Support Medical Cannabis Clinical Trial
Statement from Vireo Health of New York on Governor Cuomo’s State of the State Address Proposal to Legalize the Adult-Use of Cannabis
The following statement can be attributed to Ari Hoffnung, CEO of Vireo Health of New York, one of only 10 organizations licensed in the state to grow, cultivate, manufacture and...
Read more
Vireo Health Employees Ratify First Cannabis Union Contract in Maryland History with UFCW Local 27
TOWSON, Md., Jan. 7, 2020 /PRNewswire/ -- United Food and Commercial Workers Local 27 (UFCW27) and Vireo Health International, Inc. ("Vireo" or "the Company") (CNSX: VREO; OTCQX: VREOF), today announced that...
Read more
Vireo Health Launches Lower-THC ‘LiteBud’ Brand
MINNEAPOLIS, Jan. 6, 2020 /PRNewswire/ -- Vireo Health International, Inc. ("Vireo" or the "Company") (CNSX: VREO, OTCQX: VREOF), a leading physician-led, science-focused multi-state cannabis company, today announced the launch of LiteBud,...
Read more
Vireo Health CEO and Founder Kyle Kingsley, M.D. Signs CEO Action for Diversity & Inclusion™ Pledge
MINNEAPOLIS, Dec. 17, 2019 /PRNewswire/ -- Vireo Health International, Inc. ("Vireo" or the "Company") (CNSX: VREO; OTCQX: VREOF), a leading physician-founded, science-focused multi-state cannabis company today announced that the Company's CEO...
Read more View More >